Rhinostop, drops 0.05% 10 ml

Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenomimetic activity, causes narrowing of blood vessels of nasal mucosa, thus eliminating edema and hyperemia of nasal mucosa, restores nasal passageways patency, facilitates nasal breathing.

The drug takes effect within a few minutes after application and lasts up to 10 hours.

Pharmacokinetics

The drug is practically not absorbed when applied topically, so its concentration in the blood plasma is very low (not determined by modern analytical methods).

Indications

Used for acute respiratory diseases with symptoms of rhinitis (runny nose), acute allergic rhinitis, sinusitis, otitis media (as part of combination therapy to reduce swelling of the nasopharyngeal mucosa), runny nose for allergies and colds.

Preparing the patient for diagnostic manipulations in the nasal passages.

Pharmacological effect

Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenomimetic activity, causes a narrowing of the blood vessels of the nasal mucosa, thus eliminating swelling and hyperemia of the nasal mucosa, restores the patency of the nasal passages, and facilitates nasal breathing.

The effect of the drug begins a few minutes after its use and lasts up to 10 hours.

Pharmacokinetics

When applied topically, the drug is practically not absorbed, so its concentration in the blood plasma is very low (not determined by modern analytical methods).

Active ingredient

Xylometazoline

Composition

1 ml drops contains:

Active ingredient:

xylometazoline (in the form of hydrochloride) 0.0005 g;

Excipients:

benzalkonium chloride;

disodium salt of ethylenediaminetetraacetic acid (trilon B);

potassium phosphate monosubstituted;

sodium phosphate disubstituted;

sodium chloride;

purified water.

Pregnancy

During pregnancy and lactation, Rinostop should be used only after a thorough assessment of the risk-benefit ratio for the mother and fetus; recommended doses should not be exceeded.

Contraindications

Hypersensitivity to xylometazoline and other components of the drug, arterial hypertension, tachycardia, severe atherosclerosis, glaucoma, atrophic rhinitis, surgical interventions on the meninges (in history), conditions after transsphenoidal hypophysectomy, children’s age (up to 2 years – for 0.05% spray, up to 6 years for 0.1% spray), pregnancy.

Do not use during therapy with monoamine oxidase inhibitors and tricyclic antidepressants (including the period of 14 days after their discontinuation).

Side Effects

With frequent and/or prolonged use: irritation of the mucous membrane, burning, tingling, sneezing, dry nasal mucosa, hypersecretion.

Rarely: swelling of the nasal mucosa (more often with long-term use), palpitations, heart rhythm disturbances, increased blood pressure, headache, vomiting, sleep disorders, visual disturbances.

With long-term use in high doses: depressive state.

Storage conditions

In a place protected from light, at a temperature of 0–25 °C

Shelf life

3 years

Manufacturer

Lecco CJSC, Russia